Last reviewed · How we verify
Vehicle Topical Foam
Vehicle Topical Foam is an inert formulation base designed to deliver active pharmaceutical ingredients to the skin surface.
Vehicle Topical Foam is an inert formulation base designed to deliver active pharmaceutical ingredients to the skin surface. Used for Topical delivery vehicle for dermatological agents.
At a glance
| Generic name | Vehicle Topical Foam |
|---|---|
| Also known as | Vehicle Control (Placebo) |
| Sponsor | Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
As a vehicle or excipient formulation, this foam serves as a delivery system rather than having its own therapeutic mechanism. It is designed to provide optimal skin penetration, retention, and cosmetic acceptability for topical medications. The foam format enhances spreadability and patient compliance compared to other topical delivery forms.
Approved indications
- Topical delivery vehicle for dermatological agents
Common side effects
Key clinical trials
- Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (PHASE4)
- A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis (PHASE3)
- A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis (PHASE3)
- Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) (PHASE3)
- A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) (PHASE2)
- Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch (NA)
- Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) (PHASE3)
- To Evaluate the Efficacy and Safety of Minocycline Hydrochloride Foam in the Treatment of Moderate-to-severe Acne Vulgaris (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: